In the age of personalized medicine, oncologists can routinely order biomarker tests for their patients with advanced NSCLC—and use the results to consider more tailored treatment.
Treatment decisions are increasingly informed by appropriate diagnostic technique. Testing for molecular biomarkers, such as EGFR mutation and ALK rearrangement, represents the cutting edge of pathology in advanced NSCLC.
Collection of sufficient tissue by pulmonologists, interventional radiologists, thoracic surgeons, and other physicians who perform biopsies is a critical step in the biomarker testing process in NSCLC.
Patients look to allied healthcare professionals (oncology nurse practitioners, physician assistants, and nurses) to learn more about how biomarkers, such as EGFR mutations and ALK rearrangements, inform the cancer treatment plan.